吉瑞替尼对比安慰剂用于FLT3-ITD阳性急性髓系白血病移植后的健康相关生活质量
血液与骨髓移植临床试验网络开展的3期随机试验,比较FLT3-ITD阳性急性髓系白血病异基因造血干细胞移植后吉瑞替尼与安慰剂对健康相关生活质量的影响;各时间点两组生活质量评分无差异,尽管吉瑞替尼治疗相关不良事件更多,但副作用困扰无差异。
要点
- 移植后吉瑞替尼组与安慰剂组在各时间点健康相关生活质量评分无差异。
- 两组达到临床意义改善的时间相似。
- 尽管吉瑞替尼治疗相关不良事件更多,副作用困扰评分两组无差异。
核心结论
- 对于接受异基因造血干细胞移植的FLT3-ITD阳性急性髓系白血病患者,吉瑞替尼维持治疗与健康相关生活质量或患者报告的副作用影响无差异。
研究设计与样本
- 血液与骨髓移植临床试验网络开展的3期随机试验,比较异基因造血干细胞移植后吉瑞替尼与安慰剂。
- 使用FACT-BMT、FACT-Leu和EQ-5D-5L在移植后随机化时、第29天、第3、6、12、18、24个月和/或治疗结束时测量健康相关生活质量。
主要发现
- 各时间点两组健康相关生活质量评分无差异。
- 两组临床意义改善和达到改善的时间相似。
- 尽管吉瑞替尼组治疗相关不良事件更多,但两组对「被治疗副作用困扰」问题的回答无差异。
- MRD阳性和阴性亚组分析显示两组健康相关生活质量无差异。
- 健康相关生活质量完成率在所有时间点和测量中均>70%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Blood and Marrow Transplant (BMT) Clinical Trials Network conducted a phase 3 randomized trial comparing gilteritinib with placebo after allogeneic hematopoietic cell transplantation (HCT) for FLT3-ITD+ acute myeloid leukemia (AML). The primary analysis demonstrated no statistically significant difference in relapse-free survival (RFS); however, patients with FLT3-ITD measurable residual disease (MRD) peri-HCT had significantly longer RFS with gilteritinib. This analysis investigates the effect of post-HCT gilteritinib vs placebo on health-related quality of life (HRQOL). HRQOL was measured with Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), FACT-Leukemia (FACT-Leu), and EuroQOL-5 Dimensions (EQ-5D-5L) at post-HCT randomization; day 29; months 3, 6, 12, 18, 24; and/or end of therapy. HRQOL and clinically meaningful differences were summarized using descriptive statistics and compared using mixed model repeated measures to evaluate longitudinal change from baseline and stratified Cox model to evaluate time to improvement. HRQOL completion rate was acceptable (>70%) across all time points and measures. There were no differences in HRQOL scores at any time point between cohorts. Clinically meaningful and time to improvement in HRQOL were similar in both arms. Despite higher treatment-emergent adverse effects with gilteritinib, response to the question of being "bothered by side effects of treatment" did not differ between groups. Subgroup analysis of MRD-positive and negative patients demonstrated no differences in HRQOL between arms. For patients with FLT3-ITD+ AML undergoing HCT, gilteritinib maintenance was not associated with any difference in HRQOL or patient-reported impact of side effects. This trial was registered at www.ClinicalTrials.gov as #NCT02997202.
引用
- Hamilton BK, Pandya BJ, Ivanescu C, et al. Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia. Blood Adv. 2024. PMID: 39167766. doi:10.1182/bloodadvances.2024013746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。